Centaur Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 20.00 Cr
- Paid Up Capital ₹ 18.50 Cr
- Company Age 44 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 308.00 Cr
- Satisfied Charges ₹ 239.90 Cr
- Revenue Growth -6.18%
- Profit Growth -42.94%
- Ebitda -40.72%
- Net Worth 12.37%
- Total Assets 5.84%
About Centaur Pharmaceuticals
Centaur Pharmaceuticals Private Limited (CPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 15 October 1980 and has a history of 44 years and four months. Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Centaur Pharmaceuticals Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 20.00 Cr and a paid-up capital of Rs 18.50 Cr.
The company currently has active open charges totaling ₹308.00 Cr. The company has closed loans amounting to ₹239.90 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Centaur Pharmaceuticals Private Limited India is Pritam Khawale as COMPANY SECRETARY. Sharadchandra Abhyankar, Shreekant Sawant, Albert Taura, and Four other members serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24230MH1980PTC023291
- Company No.
023291
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Oct 1980
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Centaur Pharmaceuticals Private Limited offer?
Centaur Pharmaceuticals Private Limited offers a wide range of products and services, including Personal Care, Oral Care, Vitamins & Supplements, Mineral Supplements, Health Conditions, Kidney Care, Skin Care, Facewash, Respiratory Care, Cold & Cough.
Who are the key members and board of directors at Centaur Pharmaceuticals?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shreekant Sawant  | Managing Director | 01-Aug-2008 | Current |
| Pritam Khawale | Company Secretary | 18-Aug-2009 | Current |
| Shivanand Sawant | Managing Director | 15-Oct-1980 | Current |
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sharadchandra Abhyankar | Director | 11-Aug-2016 | Current |
| Albert Taura | Director | 11-Aug-2016 | Current |
| Supriya Desai | Whole-Time Director | 21-Dec-2021 | Current |
| Rakhi Kadam | Whole-Time Director | 24-Mar-2015 | Current |
| Smita Phal | Whole-Time Director | 22-Jun-2011 | Current |
Financial Performance of Centaur Pharmaceuticals.
Centaur Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 6.18% decrease. The company also saw a substantial fall in profitability, with a 42.94% decrease in profit. The company's net worth Soared by an impressive increase of 12.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Centaur Pharmaceuticals?
In 2024, Centaur Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Atul LimitedSharadchandra Abhyankar is a mutual person
Instasafe Technologies Private LimitedSharadchandra Abhyankar is a mutual person
Whiteoak Capital Trustee LimitedSharadchandra Abhyankar is a mutual person
Dreamfolks Services LimitedSharadchandra Abhyankar is a mutual person
Abm Knowledgeware LimitedSharadchandra Abhyankar is a mutual person
Minesfield Advisory Services LlpShreekant Sawant and Shivanand Sawant are mutual person
Charges (Loans)
₹308.00 Cr
₹239.90 Cr
Charges Breakdown by Lending Institutions
- State Bank Of India : 308.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 May 2011 | State Bank Of India | ₹154.00 Cr | Open |
| 03 Aug 2006 | State Bank Of India | ₹154.00 Cr | Open |
| 26 May 2015 | Tata Capital Financial Services Limited | ₹1.70 Cr | Satisfied |
| 27 Jan 2015 | Tata Capital Financial Services Limited | ₹3.00 Cr | Satisfied |
| 19 May 2014 | Tata Capital Financial Services Limited | ₹12.50 Cr | Satisfied |
How Many Employees Work at Centaur Pharmaceuticals?
Centaur Pharmaceuticals has a workforce of 3274 employees as of Oct 11, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Centaur Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Centaur Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
